300 American Road
423 articles with Immunomedics, Inc.
In addition to its fourth-quarter financial report, Morris Plains, NJ-based Immunomedics announced that its president, chief executive officer and board member, Michael Pehl, was stepping down for personal reasons.
IMMUNOMEDICS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit against Immunomedics, Inc..
The American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) is being held in San Francisco from February 14-16. Ahead of the conference, several companies have announced presentations. Here’s a look at just a few.
Immunomedics was hoping for a green light from the U.S. Food and Drug Administration for its triple-negative breast cancer treatment, sacituzumab govitecan. However, this morning the company announced that approval will not likely be coming any time soon.
Because of the government shutdown, which as of Monday, January 14 is into its fourth week, 40 percent of the U.S. FDA employees were furloughed. However, the two approvals described here should still be on track.
Block & Leviton LLP Files Securities Class Action Against Immunomedics, Inc. ("IMMU"); Investors Are Encouraged to Contact the Firm
Block & Leviton LLP announces that it has filed a securities fraud class action against Immunomedics, Inc. and certain of its officers and/or directors
IMMUNOMEDICS LOSSES ALERT: BERNSTEIN LIEBHARD LLP ANNOUNCES INVESTIGATION OF IMMUNOMEDICS, INC. - IMMU
Bernstein Liebhard LLP is investigating potential securities fraud claims on behalf of shareholders of Immunomedics, Inc. resulting from allegations that Immunomedics and/or its executives may have issued materially misleading business information to the investing public.
Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.
Immunomedics Announces Agreement With University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) Into Prostate Cancer
The Prostate Cancer Clinical Trials Consortium, to investigate Immunomedics’ lead antibody-drug conjugate product candidate, sacituzumab govitecan, in an investigator-sponsored Phase 2 trial in patients with advanced castration-resistant prostate cancer.
Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250M
Royalty Pharma has also purchased $75 million in common stock of Immunomedics.
Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) in Patients With Relapsed or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC)
The independent centrally-reviewed (ICR) median DOR was 9.1 months. These efficacy data are summarized in the table below.
The company appointed former Celgene president Michael Pehl as CEO and Brendan Delaney as CCO.
Total revenue was $0.7 million for both quarters ended September 30, 2017 and September 30, 2016.
Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017
To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 7899497.
Immunomedics Announces Agreements To Exchange Approximately $80.0 Million Of Its 4.75% Convertible Senior Notes Due 2020 For Common Stock
Immunomedics Presents Interim Phase II Results With Sacituzumab Govitecan (IMMU-132) In Patients With Pretreated Metastatic Urothelial Cancer
Immunomedics Announces Publication Of Phase II Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer
Immunomedics Announces Fiscal 2017 Results And Strategic Developments; Reiterates Guidance On BLA Submission Timeline
Published Results From Clinical Trials Demonstrate Therapeutic Potential For Immunomedics’ Sacituzumab Govitecan (IMMU-132) In The Treatment Of Metastatic Solid Cancers